Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3360 studies found for:    non-Hodgkin's lymphoma
Show Display Options
Rank Status Study
21 Unknown  Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib
22 Not yet recruiting Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Chiauranib
23 Completed Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade;   Drug: Temsirolimus
24 Completed Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Zevalin-BuCyE
25 Unknown  Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
26 Terminated Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkins Lymphoma
Intervention: Drug: alemtuzumab
27 Active, not recruiting Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Condition: High Risk Non-Hodgkin's Lymphoma
Interventions: Biological: Rituximab;   Biological: Interleukin-2
28 Completed A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: YM155;   Biological: Rituximab
29 Unknown  PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care
Condition: Non-Hodgkin Lymphoma
Interventions: Other: Implementation tools;   Other: Standard intervention
30 Active, not recruiting Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Bendamustine hydrochloride
31 Completed Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
Conditions: Tumors;   Non-Hodgkins's Lymphoma
Intervention: Drug: omeprazole and bortezomib
32 Terminated Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
Conditions: Indolent Non Hodgkin's Lymphoma (iNHL);   Chronic Lymphocytic Leukaemia (CLL)
33 Recruiting DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Conditions: B-cell Non-Hodgkin Lymphoma;   Aggressive
Interventions: Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
34 Completed Treatment for Subjects With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: pegfilgrastim;   Drug: Filgrastim
35 Terminated Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Standard CHOP;   Drug: Bi-CHOP (dose intensified CHOP)
36 Terminated Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: LBH589
37 Completed
Has Results
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Drug: TG-0054 (2.24 mg/kg);   Drug: TG-0054 (3.14 mg/kg)
38 Withdrawn Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Vorinostat in combination with Bortezomib
39 Recruiting A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Intervention: Drug: tazemetostat
40 Completed Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Bendamustine HCl

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.